Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

NCT00091689

Last updated date
Study Location
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, , United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Have melanoma cutaneous metastasis or lentigo maligna melanoma unresectable and for which standard curative or palliative measures do not exist or are no longer effective.

- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

- Have a life expectancy of 4 months

- Have normal organ and bone marrow function

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Need for non-steroidal anti-inflammatory drugs (NSAIDs) during the study


- Have a body mass index (BMI)> 30 kg/m2


- Have a history of, or clinical evidence of, myocardial ischemia, congestive heart
failure, or myocardial arrhythmias requiring treatment within the past 6 months


- Have uncontrolled intercurrent or chronic illness, but not limited to, ongoing or
active infection such as hepatitis B or C, immune dysfunction such as autoimmune
disease, endocrine dysfunction such as hypo- or hyperthyroidism, psychiatric illness
such as depression or suicidal tendency or social situations that would limit
compliance with study requirements


- Have a history of disease requiring ongoing steroid treatment


- Have a history of seizure disorder (other than febrile seizures in childhood)


- Have a history of clinically significant coagulation or bleeding disorders or
abnormalities


- Are HIV positive. HIV positive subjects are excluded from the study because of
possible interactions with the immunomodulatory effects of 852A and because of
potential pharmacokinetic interactions associated with combination retroviral therapy.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

MelanomaEncorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E/K Positive Melanoma
NCT04657991
  1. Orlando, Florida
  2. Orlando, Florida
  3. Orlando, Florida
  4. Temple, Texas
  5. Aventura, Florida
  6. Knoxville, Tennessee
  7. Nashville, Tennessee
  8. Nashville, Tennessee
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaStudy Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
NCT01909453
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Fayetteville, Arkansas
  6. Rogers, Arkansas
  7. Orange County, California
  8. Orange, California
  9. Orange, California
  10. Aurora, Colorado
  11. Boulder, Colorado
  12. Colorado Springs, Colorado
  13. Denver, Colorado
  14. Lakewood, Colorado
  15. Parker, Colorado
  16. Pueblo, Colorado
  17. Chicago, Illinois
  18. Chicago, Illinois
  19. Chicago, Illinois
  20. Chicago, Illinois
  21. Goshen, Indiana
  22. Goshen, Indiana
  23. Grand Rapids, Michigan
  24. Grand Rapids, Michigan
  25. Grand Rapids, Michigan
  26. Jackson, Mississippi
  27. Jackson, Mississippi
  28. Hackensack, New Jersey
  29. Rochester, New York
  30. Dallas, Texas
  31. Burlington, Vermont
  32. Burlington, Vermont
  33. Burlington, Vermont
  34. Alexandria, Virginia
  35. Arlington, Virginia
  36. Fairfax, Virginia
  37. Fairfax, Virginia
  38. Fairfax, Virginia
  39. Falls Church, Virginia
  40. Gainesville, Virginia
  41. Leesburg, Virginia
  42. Woodbridge, Virginia
  43. Wenatchee, Washington
  44. Caba, Buenos Aires
  45. Buenos Aires, Ciudad Autónoma DE Buenosaires
  46. Buenos Aires, Ciudad Autónoma DE Buenosaires
  47. Buenos Aires, Ciudad Autónoma DE Buenosaires
  48. Buenos Aires, Ciudad Autónoma DE Buenosaires
  49. Buenos Aires, Ciudad Autónoma DE Buenosaires
  50. Buenos Aires, Ciudad Autónoma DE Buenosaires
  51. Gateshead, New South Wales
  52. Southport, Queensland
  53. Southport, Queensland
  54. Southport, Queensland
  55. Woolloongabba, Queensland
  56. Melbourne, Victoria
  57. Prahran, Victoria
  58. Nedlands, Western Australia
  59. Recife, Pernambuco
  60. Ijuí, RIO Grande DO SUL
  61. Porto Alegre, RIO Grande DO SUL
  62. Barretos, SAO Paulo
  63. Natal,
  64. Rio de Janeiro,
  65. Sao Paulo,
  66. Calgary, Alberta
  67. Toronto, Ontario
  68. Toronto, Ontario
  69. Toronto, Ontario
  70. Montreal, Quebec
  71. Montreal, Quebec
  72. Montreal, Quebec
  73. Montreal, Quebec
  74. Québec, Quebec
  75. Bogotá, Distrito Capital DE Bogotá
  76. Bogotá, Pbx (57-1)
  77. Brno, Jihomoravský KRAJ
  78. Praha 10, Praha, Hlavní Mesto
  79. Praha 2, Praha, Hlavní Mesto
  80. Brno,
  81. Olomouc,
  82. Ostrava Poruba,
  83. Praha,
  84. Nice, Alpes-maritimes
  85. Bordeaux, Gironde
  86. Grenoble, Isère
  87. Reims, Marne
  88. Lille, Nord
  89. Lyon, Rhone
  90. Lyon, Rhône
  91. Le Mans, Sarthe
  92. Villejuif, Val-de-marne
  93. Boulogne-Billancourt,
  94. Lille,
  95. Lyon,
  96. Nice,
  97. Paris,
  98. Paris,
  99. Paris,
  100. Paris,
  101. Pierre-bénite,
  102. Strasbourg,
  103. Templemars,
  104. Villejuif,
  105. Freiburg im Breisgau, Baden-württemberg
  106. Heidelberg, Baden-württemberg
  107. Mannheim, Baden-württemberg
  108. Tübingen, Baden-württemberg
  109. Ulm, Baden-württemberg
  110. München, Bayern
  111. Regensburg, Bayern
  112. Regensburg, Bayern
  113. Würzburg, Bayern
  114. Frankfurt, Hessen
  115. Kassel, Hessen
  116. Kassel, Hessen
  117. Buxtehude, Niedersachsen
  118. Buxtehude, Niedersachsen
  119. Bonn, Nordrhein-westfalen
  120. Minden, Nordrhein-westfalen
  121. Minden, Nordrhein-westfalen
  122. Mainz, Rheinland-pfalz
  123. Magdeburg, Sachsen-anhalt
  124. Dresden, Sachsen
  125. Leipzig, Sachsen
  126. Berlin, Schleswig-holstein
  127. Luebeck, Schleswig-holstein
  128. Lübeck, Schleswig-holstein
  129. Berlin,
  130. Bonn,
  131. Bonn,
  132. Dresden,
  133. Dresden,
  134. Erfurt,
  135. Erfurt,
  136. Essen,
  137. Freiburg,
  138. Gera,
  139. Gera,
  140. Gera,
  141. Hamburg,
  142. Hannover,
  143. Hannover,
  144. Hannover,
  145. Heidelberg,
  146. Homburg,
  147. Kiel,
  148. Lübeck,
  149. Magdeburg,
  150. Magdeburg,
  151. Mainz,
  152. Mannheim,
  153. Minden,
  154. Münster,
  155. Nürnberg,
  156. Regensburg,
  157. Tübingen,
  158. Ulm,
  159. Ulm,
  160. Athens, Attiki
  161. Athens,
  162. Athens,
  163. Piraeus,
  164. Debrecen, Hajdú-bihar
  165. Budapest,
  166. Budapest,
  167. Szolnok,
  168. Ramat Gan, Tel-aviv
  169. Haifa,
  170. Jerusalem,
  171. Torrette Site, Ancona
  172. Napoli, Campania
  173. Roma, Lazio
  174. Roma, Lazio
  175. Lecco, Lombardia
  176. Milan, Lombardia
  177. Monza, Lombardia
  178. Rozzano, Lombardia
  179. Rozzano, Lombardia
  180. Candiolo, Torino
  181. Pisa, Toscana
  182. Terni, Umbria
  183. Padua, Veneto
  184. Bari,
  185. Bergamo,
  186. Bologna,
  187. Genoa,
  188. Milano,
  189. Napoli,
  190. Padova,
  191. Pavia,
  192. Ragusa,
  193. Siena,
  194. Torino,
  195. Fukuoka-shi, Fukuoka
  196. Matsumoto, Nagano
  197. Chuo-ku, Tokyo
  198. Niigata,
  199. Osaka, Ôsaka
  200. Gangnam-Gu, Seoul Teugbyeolsi
  201. Songpa-Gu, Seoul Teugbyeolsi
  202. Seoul,
  203. Seoul,
  204. Seoul,
  205. Seoul,
  206. Mexico,
  207. Mexico,
  208. Nijmegen, Gelderland
  209. Heerlen, Limburg
  210. Amsterdam, Noord Holland
  211. Breda, Noord-brabant
  212. Eindhoven, Noord-brabant
  213. Veldhoven, Noord-brabant
  214. Zwolle, Overijssel
  215. Enschede,
  216. Groningen,
  217. Leiden,
  218. Maastricht,
  219. Rotterdam,
  220. Rotterdam,
  221. Sittard-Geleen,
  222. Oslo,
  223. Oslo,
  224. Oslo,
  225. Warsaw, Mazowieckie
  226. Warszawa, Mazowieckie
  227. Warszawa,
  228. Lisbon, Lisboa
  229. Porto, Proto
  230. Almada,
  231. Lisboa,
  232. Lisboa,
  233. Lisboa,
  234. Porto,
  235. Moscow,
  236. St. Petersburg,
  237. Singapore,
  238. Singapore,
  239. Singapore,
  240. Bratislava,
  241. Bratislava,
  242. Bratislava,
  243. Poprad,
  244. Pretoria,
  245. Pretoria,
  246. Jerez De La Frontera, Andalucía
  247. Oviedo, Asturias
  248. Barcelona, Cataluña
  249. El Palmar, Murcia
  250. Pamplona, Navarra
  251. Pamplona, Navarra
  252. Alicante,
  253. Badalona,
  254. Barcelona,
  255. Barcelona,
  256. Barcelona,
  257. Barcelona,
  258. Donostia-san Sebastián,
  259. Dos Hermanas,
  260. Granada,
  261. La Coruna,
  262. Lleida,
  263. Lleida,
  264. Madrid,
  265. Madrid,
  266. Madrid,
  267. Madrid,
  268. Majadahonda,
  269. Malaga,
  270. Sevilla,
  271. Sevilla,
  272. Sevilla,
  273. Valencia,
  274. Göteborg,
  275. Lund,
  276. Solna,
  277. Uppsala,
  278. Zurich, Zürich (DE)
  279. Bern,
  280. Zürich,
  281. Zürich,
  282. Zürich,
  283. Bornova,
  284. Izmir,
  285. Izmir,
  286. Cambridge, Cambridgeshire
  287. Preston, Lancashire
  288. London, London, CITY OF
  289. Guildford, Surrey
  290. Bebington, Wirral
  291. Sheffield, York
  292. Broomfield,
  293. Leeds,
  294. London,
  295. Manchester,
  296. Oxford,
  297. Oxford,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
NCT03159117
  1. New York, New York
ALL GENDERS
18 Years+
years
MULTIPLE SITES
MelanomaPhase I Oncovir Poly IC:LC and NY-ESO-1/gp100
NCT01008527
  1. Tampa, Florida
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
Official Title  ICMJE Not Provided
Brief Summary Study 1501-852A is a Phase 1 Study with the objective of determining safety and the highest tolerated dose of an immune response modifier cream directly applied to advanced, inoperable, melanoma skin lesions. The study will also measure blood levels of the drug and examine the potential anti-tumor activity of the cream.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Melanoma
Intervention  ICMJE Drug: 852A
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE Not Provided
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE January 2006
Actual Primary Completion Date January 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Have melanoma cutaneous metastasis or lentigo maligna melanoma unresectable and for which standard curative or palliative measures do not exist or are no longer effective.
  • Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
  • Have a life expectancy of 4 months
  • Have normal organ and bone marrow function

Exclusion Criteria:

  • Need for non-steroidal anti-inflammatory drugs (NSAIDs) during the study
  • Have a body mass index (BMI)> 30 kg/m2
  • Have a history of, or clinical evidence of, myocardial ischemia, congestive heart failure, or myocardial arrhythmias requiring treatment within the past 6 months
  • Have uncontrolled intercurrent or chronic illness, but not limited to, ongoing or active infection such as hepatitis B or C, immune dysfunction such as autoimmune disease, endocrine dysfunction such as hypo- or hyperthyroidism, psychiatric illness such as depression or suicidal tendency or social situations that would limit compliance with study requirements
  • Have a history of disease requiring ongoing steroid treatment
  • Have a history of seizure disorder (other than febrile seizures in childhood)
  • Have a history of clinically significant coagulation or bleeding disorders or abnormalities
  • Are HIV positive. HIV positive subjects are excluded from the study because of possible interactions with the immunomodulatory effects of 852A and because of potential pharmacokinetic interactions associated with combination retroviral therapy.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00091689
Other Study ID Numbers  ICMJE 1501-852A
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Pfizer
Verification Date October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP